HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

ketazolam (Marcen)

structure

Also Known As:

Marcen; Iquinosa brand of ketazolam; MI 49001; Pfizer brand of Ketazolam; Pharmacia brand of ketazolam; Sedotime; Solatran; U 28,774; Unakalm; 11-chloro-8,12b-dihydro-2,8-dimethyl-12b-phenyl-4H-(1,3)oxazino(3,2-d)(1,4)benzodiazepine-4,7(6H)-dione

Networked: 4 relevant articles (2 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 60
- 2-Ring Heterocyclic Compounds
  - Benzazepines: 5
    - Benzodiazepines: 5199
      - ketazolam: 4

Related Diseases

1.	Multiple Sclerosis 11/01/1984 - "Ketazolam is a relatively safe and clinically effective antispasticity agent (especially for patients with multiple sclerosis). " 08/01/1986 - "This double-blind cross-over study of 14 severely spastic inpatients with chronic multiple sclerosis reveals that once-daily doses of ketazolam, a new drug, are effective in reducing spasticity in a significant proportion of patients without significant side-effects. "
2.	Muscle Spasticity (Spastic) 08/01/1986 - "This double-blind cross-over study of 14 severely spastic inpatients with chronic multiple sclerosis reveals that once-daily doses of ketazolam, a new drug, are effective in reducing spasticity in a significant proportion of patients without significant side-effects. "
3.	Anxiety Disorders (Anxiety Disorder) 01/01/1988 - "In a multicenter, double-blind trial, 63 elderly patients who had experienced a generalized anxiety disorder for at least one month were randomly assigned to receive 15 mg of ketazolam (n = 31) or placebo (n = 32) daily for 15 days. " 01/01/1988 - "A multicenter, double-blind, between-patient trial comparing two doses of ketazolam (15 and 30 mg) with placebo, each given once daily, in the evening, to 92 outpatients affected by generalized anxiety disorders for at least 1 month, was carried out. "